BI
BioArctic
BIOA.ST·OMXStockholm SEFounded 2003160 employees
Mid CapbiotechPublicNeurology
Platform: Lecanemab partner
Market Cap
$3B
All Drugs
3
Clinical Trials
4
Failed / Terminated
0
FDA Approved
0
Stock Price & Catalysts (BIOA.ST)
Loading BIOA.ST stock data...
Drug Pipeline (3 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Olpavorutinib | BIO-7034 | Preclinical | 1 | PARP | EoENarcolepsy | ||
| BIO-3214 | BIO-3214 | Preclinical | 2 | MDM2 | IPF | ||
| Gozecagene | BIO-2010 | Phase 1 | 1 | GPRC5D | NMOSDACC |
SEC Filings & Financial Documents
SEC filings are not available for OMX-listed companies.
BioArctic trades on OMX (SE). SEC EDGAR only covers US-listed issuers.
Insider Trading Activity
Insider trading data is not available for non-US exchanges.
Catalyst Events (3)